Equities Analysts Offer Predictions for BCRX FY2025 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for shares of BioCryst Pharmaceuticals in a research report issued on Tuesday, May 6th. Cantor Fitzgerald analyst S. Seedhouse now forecasts that the biotechnology company will post earnings of $0.09 per share for the year, up from their previous forecast of ($0.27). Cantor Fitzgerald currently has a "Overweight" rating and a $20.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter in the prior year, the company earned $0.28 earnings per share. The company's revenue for the quarter was up 40.8% on a year-over-year basis.

Other analysts have also recently issued reports about the stock. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Royal Bank of Canada reiterated an "outperform" rating and set a $13.00 price objective (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. JMP Securities reiterated a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, JPMorgan Chase & Co. increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $16.56.

BioCryst Pharmaceuticals Stock Down 2.6%

NASDAQ BCRX traded down $0.27 during trading hours on Thursday, hitting $10.07. 3,054,322 shares of the stock were exchanged, compared to its average volume of 3,924,949. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -16.51 and a beta of 1.08. The stock has a 50-day moving average of $7.92 and a 200 day moving average of $7.90. BioCryst Pharmaceuticals has a 12-month low of $5.35 and a 12-month high of $11.11.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $32,000. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $33,000. GAMMA Investing LLC raised its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after acquiring an additional 5,449 shares during the period. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at $46,000. Finally, R Squared Ltd bought a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $48,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.